IR Information
FY2025 Financial Results Presentation Materials with Script
Notice Concerning Recording of Extraordinary Income and Losses (Consolidated and Non-consolidated)
Results Presentation of FY2025
FY2025 Summary of Consolidated Financial Statements
Product Information
Price Revision for Denka Chloroprene
Notice Regarding Results of Tender Offer for Share Certificates, Etc. of KAINOS Laboratories, Inc. (Securities Code: 4556)
Announcement of Extraordinary Gains (Gain on Sale of Investment Securities)